All articles tagged with #immune activation
Scientists at Stanford have developed a synthetic molecule, PIP-CpG, that targets and kills breast and pancreatic cancers in mice with as few as three doses by delivering immune-activating agents directly to tumors, transforming the tumor microenvironment and showing promising results for future human treatments.
Researchers have discovered a new cancer treatment approach that targets the interaction between ERK and MyD88 proteins, rather than enzyme activity, to induce cancer cell death and activate the immune system. This method, tested in mouse models and patient-derived cells, offers a dual benefit of reducing tumor size and enhancing immune response, potentially minimizing side effects and recurrence. The study, published in Nature Communications, suggests this strategy could complement existing therapies and is a promising step towards more effective cancer treatments.
Research led by the University of Tübingen and partners at Stanford University, Emory University, and the Cincinnati Children's Hospital Medical Center has found that infants and young children have unique and effective immune responses to SARS-CoV-2. The study revealed that infants mount durable antibody responses for up to 300 days, with robust mucosal and systemic immune reactions. These findings suggest the potential for designing vaccine formulations that leverage these innate immune system activation pathways to avoid excessive inflammation.